Enzalutamide/Abiraterone Acetate/Prednisolone Combo in mHSPC Not Recommended
September 11th 2022Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.
Read More
No Significant Improvement of DFS Seen in High-Risk RCC With Adjuvant Nivolumab/Ipilimumab
September 11th 2022Adjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high risk for relapse after nephrectomy failed to significantly improve disease-free survival vs placebo in part A of the phase 3 CheckMate 914 trial.
Read More
Promising Results Demonstrated With Blood Tests for Early Cancer Detection
September 11th 2022Positive signals from a blood-based multi-cancer early detection test led to cancer diagnoses after the test indicated potential cancers in 1.4% of individuals from an otherwise healthy cohort of participants in the the prospective PATHFINDER study.
Read More
Xevinapant Plus CRT in Locally Advanced HNSCC Shows Continued Benefit
September 11th 2022Improvement in overall survival for patients with locally advanced head and neck squamous cell carcinoma was demonstrated with xevinapant plus standard chemoradiotherapy vs matched placebo at the 5-year mark.
Read More
Updated Results Support Efficacy of Trastuzumab Deruxtecan in Metastatic Gastric/GEJ Cancer
September 11th 2022New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Read More
Frontline Tislelizumab Shows Non-Inferior OS vs Sorafenib in Unresectable HCC
September 11th 2022At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.
Read More
KEYNOTE-365 2-Year Update Shows Benefit of Pembrolizumab Plus Abiraterone in mCRPC
September 11th 2022An updated analysis of the KEYNOTE-365 study of pembrolizumab plus abiraterone showed that patients with chemotherapy-naive metastatic castration-resistant prostate cancer had prostate-specific antigen responses.
Read More
Sacituzumab Govitecan Shows Strong ORR, PFS Benefit in HER2-Low/IHC0 Metastatic Breast Cancer
September 10th 2022The antibody-drug conjugate sacituzumab govitecan demonstrated superior overall response rate and progression-free survival in patients with breast cancer with limited options due to lack of high HER2 expression.
Read More
Lasofoxifene Improves Certain Responses in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
September 10th 2022While lasfoxifene alone did not meet the primary end points that researchers set out for it, they did find that it improves responses in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Read More
Combination of Abemaciclib and Trastuzumab Improves OS in HR+, HER2+ Advanced Breast Cancer
September 10th 2022Adding abemaciclib to trastuzumab improved overall survival in women with with hormone receptor–positive, HER2-positive advanced breast cancer, according to new findings discussed at the 2022 ESMO Congress.
Read More
Although the combination use of lenvatinib plus pembrolizumab did not induce statistically significant differences in the co-primary end points, the LEAP-002 trial induced the longest seen median overall survival with lenvatinib monotherapy in patients with unresectable HCC.
Read More
Dalpiciclib Improves PFS in the First-Line for HR+/HER2– Advanced Breast Cancer
September 9th 2022The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.
Read More
CLDN6 CAR T-Cell Therapy Elicits Clinical Activity in Relapsed/Refractory Advanced Solid Tumors
September 9th 2022The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Read More
Adding Oleclumab to Durvalumab and Chemotherapy Does Not Reach Clinical Benefit in Advanced TNBC
September 9th 2022Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.
Read More
Sactiuzumab Govitecan Significantly Improves OS in Pretreated HR+/HER2- Metastatic Breast Cancer
September 9th 2022Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.
Read More